The IGF2 Knockout KYSE-30 Polyclonal Cells product provides a heterogeneous CRISPR/Cas9-edited cell population derived from the KYSE-30 human esophageal squamous cell carcinoma line, in which the IGF2 gene has been disrupted to create a loss-of-function model. This polyclonal knockout pool avoids clonal selection bias, preserving biological variability inherent to polyclonal populations for robust functional studies.
KYSE-30 is a well-differentiated human esophageal squamous cell carcinoma cell line originally established from a primary tumor. As a standard model for esophageal cancer biology, it exhibits adherent growth characteristics and retains relevant oncogenic signaling pathways, making it a suitable host for targeted gene knockout investigations.
IGF2 encodes a mitogenic peptide hormone that binds the IGF-1 receptor (IGF1R) and insulin receptor isoform A, initiating IRS1-mediated activation of the PI3K/AKT cascade and GRB2/SOS-mediated stimulation of the RAS/RAF/MEK/ERK pathway. Key downstream effectors include AKT1, Cyclin D1, BCL2, and FOXO transcription factors, which collectively promote cell proliferation and survival. IGF2 bioavailability is modulated by interactions with IGFBP2, IGFBP3, and IGFBP6, and its expression is epigenetically controlled through imprinting at the 11p15.5 locus involving the H19 non-coding RNA and CTCF insulator protein.
In esophageal squamous cell carcinoma, dysregulated IGF2 expression contributes to tumor progression, apoptosis resistance, and metastatic potential. The IGF2 knockout in KYSE-30 cells enables direct interrogation of its autocrine and paracrine roles in sustaining malignant phenotypes, including assessments of downstream AKT and ERK phosphorylation and identification of compensatory signaling mechanisms.
Typical research applications encompass functional genomics, signal transduction analysis, drug screening against the IGF axis, and investigation of imprinted gene regulation. Representative assays include Western blotting for IGF2 and phospho-AKT/ERK, RT-qPCR, cell proliferation (MTT/BrdU), apoptosis (Annexin V/PI), and migration/invasion (Transwell) studies. For further details, please contact Ascent Research.
